Cargando…
The role of rhIGF-1/BP3 in the prevention of pulmonary hypertension in bronchopulmonary dysplasia and its underlying mechanism
BACKGROUND: This study aimed to determine whether postnatal treatment with recombinant human IGF-1 (rhIGF-1)/binding peptide 3 (BP3) ameliorates lung injury and prevents pulmonary hypertension (PH) in bronchopulmonary dysplasia (BPD) models. METHODS: We used two models of BPD in this study: one mode...
Autores principales: | Qu, Sehua, Shan, Lianqiang, Chen, Xin, Zhang, Zhen, Wu, Yumeng, Chen, Yun, Zhuo, Feixiang, Wang, Yitong, Dong, Huaifu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273711/ https://www.ncbi.nlm.nih.gov/pubmed/37322452 http://dx.doi.org/10.1186/s12890-023-02498-1 |
Ejemplares similares
-
rhIGF-1/BP3 Preserves Lung Growth and Prevents Pulmonary Hypertension in Experimental Bronchopulmonary Dysplasia
por: Seedorf, Gregory, et al.
Publicado: (2020) -
rhIGF-1 Therapy: A Silver Bullet for Bronchopulmonary Dysplasia
Prevention?
por: Plosa, Erin J., et al.
Publicado: (2020) -
Pilot dose-ranging of rhIGF-1/rhIGFBP-3 in a preterm lamb model of evolving bronchopulmonary dysplasia
por: Albertine, Kurt H., et al.
Publicado: (2023) -
Assessment of compatibility of rhIGF-1/rhIGFBP-3 with neonatal intravenous medications
por: Salamat-Miller, Nazila, et al.
Publicado: (2022) -
Effectiveness and safety of rhIGF1 therapy in patients with or without Laron syndrome
por: Bang, Peter, et al.
Publicado: (2020)